Loading stock data…
Sarepta Therapeutics (SRPT)
$17.02+0.17 (+1.01%)
After Hours$17.15+0.13 (+0.76%)· Last close Jun 29
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sarepta Therapeutics, Inc. in the Healthcare sector is trading at $17.02 with a market capitalization of $1.6B. Wall Street consensus targets $22.00 (23 analysts), implying a +29.3% move over the next 12 months. The stock is currently 33% below its 52-week high of $25.32, remaining 13.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +29.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $730.80M↑ | $442.93M↑ | $399.36M↓ | $611.09M↓ | $744.86M |
| Gross Profit | $622.03M↑ | $44.23M↓ | $248.58M↓ | $458.53M↓ | $607.29M |
| Operating Income | $358.43M↑ | -$410.08M↓ | -$62.88M↓ | $115.58M↑ | -$300.39M |
| Net Income | $330.96M↑ | -$282.85M↓ | -$179.95M↓ | $196.89M↑ | -$447.51M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.32%
Volume
Today's trading volume
3.74M
Recent News
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
Sarepta Therapeutics' (SRPT) Elevidys for Duchenne muscular dystrophy shows near-term stabilization,
Is Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook?
Sarepta Therapeutics recently filed a US$341.99 million shelf registration for 7,786,841 common shares tied to employee stock ownership, alongside shareholder approval of new 2026 equity incentive and employee stock purchase plans. This combination of fresh equity capacity and ESOP-related issuance highlights Sarepta’s focus on funding growth and retaining talent while preserving balance sheet flexibility. With Sarepta returning to profitability in the first quarter of 2026, we’ll now...
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SRPT vs. ARGX: Which Stock Is the Better Value Option?
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 6, Sarepta Therapeutics Inc. (NASDAQ:SRPT) delivered impressive first-quarter results as it bounced back to profitability despite facing commercialization challenges with its flagship gene therapy, ELEVIDYS. Total revenue in the quarter was $730.8 million, a decrease of […]